Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus

Michael SticherlingHautklinik, Universit&auml;tsklinikum Erlangen (Clinic of Dermatology, University Hospitals of Erlangen), Erlangen, GermanyAbstract: Cutaneous manifestations of lupus erythematosus (CLE) are manifold, presenting with unspecific skin manifestations or well-defined clinical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Michael Sticherling
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/94909ae7d09048aa86f43d9437a6b8cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:94909ae7d09048aa86f43d9437a6b8cb
record_format	dspace
spelling	oai:doaj.org-article:94909ae7d09048aa86f43d9437a6b8cb2021-12-02T00:07:28ZUpdate on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus1177-54751177-5491https://doaj.org/article/94909ae7d09048aa86f43d9437a6b8cb2011-02-01T00:00:00Zhttp://www.dovepress.com/update-on-the-use-of-topical-calcineurin-inhibitors-in-cutaneous-lupus-a6309https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Michael SticherlingHautklinik, Universit&auml;tsklinikum Erlangen (Clinic of Dermatology, University Hospitals of Erlangen), Erlangen, GermanyAbstract: Cutaneous manifestations of lupus erythematosus (CLE) are manifold, presenting with unspecific skin manifestations or well-defined clinical dermatological entities. Their relation to each other as well as to systemic lupus erythematosus is variable, yet diagnostically and therapeutically challenging. Therapeutic decisions have to be based on the activity and distribution as well as the type of skin lesions and the extent of systemic disease. Limited skin manifestations may be amply tackled by topical therapy, so far, mainly relying on corticosteroids. In many cases, however, internal treatment has to be combined by using antimalarials, in addition to strict UV-protection. The advent of topical calcineurin inhibitors has contributed substantially to the armamentarium of external treatment options. By specifically interfering with intracytoplasmic signal transduction to activate the nuclear factor of activated T-cells (NF-AT), they are able to modulate various inflammatory mechanisms. The two available compounds, pimecrolimus and tacrolimus, do not induce the skin atrophy characteristic of corticosteroids. They have been studied in a number of case reports, but only in a few randomized, comparative studies. Both are well-tolerated, but differentially effective in the various subsets of CLE. Further studies are needed to directly compare the two compounds to each other, as well as to topical corticosteroids, before final recommendations can be made.Keywords: cutaneous lupus erythematosus, calcineurin inhibitors, topical therapy, systemic therapy&nbsp; Michael SticherlingDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2011, Iss default, Pp 21-31 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Michael Sticherling Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
description	Michael SticherlingHautklinik, Universit&auml;tsklinikum Erlangen (Clinic of Dermatology, University Hospitals of Erlangen), Erlangen, GermanyAbstract: Cutaneous manifestations of lupus erythematosus (CLE) are manifold, presenting with unspecific skin manifestations or well-defined clinical dermatological entities. Their relation to each other as well as to systemic lupus erythematosus is variable, yet diagnostically and therapeutically challenging. Therapeutic decisions have to be based on the activity and distribution as well as the type of skin lesions and the extent of systemic disease. Limited skin manifestations may be amply tackled by topical therapy, so far, mainly relying on corticosteroids. In many cases, however, internal treatment has to be combined by using antimalarials, in addition to strict UV-protection. The advent of topical calcineurin inhibitors has contributed substantially to the armamentarium of external treatment options. By specifically interfering with intracytoplasmic signal transduction to activate the nuclear factor of activated T-cells (NF-AT), they are able to modulate various inflammatory mechanisms. The two available compounds, pimecrolimus and tacrolimus, do not induce the skin atrophy characteristic of corticosteroids. They have been studied in a number of case reports, but only in a few randomized, comparative studies. Both are well-tolerated, but differentially effective in the various subsets of CLE. Further studies are needed to directly compare the two compounds to each other, as well as to topical corticosteroids, before final recommendations can be made.Keywords: cutaneous lupus erythematosus, calcineurin inhibitors, topical therapy, systemic therapy&nbsp;
format	article
author	Michael Sticherling
author_facet	Michael Sticherling
author_sort	Michael Sticherling
title	Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
title_short	Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
title_full	Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
title_fullStr	Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
title_full_unstemmed	Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
title_sort	update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/94909ae7d09048aa86f43d9437a6b8cb
work_keys_str_mv	AT michaelsticherling updateontheuseoftopicalcalcineurininhibitorsincutaneouslupuserythematosus
_version_	1718403942817202176

Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus

Ejemplares similares